MSRB2

Across TCGA pan-cancer cohorts, MSRB2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MSRB2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MSRB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MSRB2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where MSRB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.844	1.000	.001	68	view →
PDAC	OS	Tertile	All	0.684	0.424	<.001	56	view →
CCRCC	DFS	Tertile	II,III,IV	0.928	0.105	.006	29	view →
LUAD	DFS	Tertile	II,III,IV	0.728	1.000	.018	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MSRB2–LSCC (DFS)

Open the LSCC breakdown →